Completed NA INTERVENTIONAL NCT00169988

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

Sertraline Alone vs. in Combination With Risperidone in the Treatment of Attenuated Positive and Negative Symptoms

Sponsor: Janssen Pharmaceutica N.V., Belgium

Conditions Prodromal Schizophrenia Psychotic Disorders

Interventions risperidone sertraline-primary

Updated 5 times since 2017 Last updated: Dec 16, 2009 Started: Mar 31, 2004 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00169988, this NA trial focuses on Prodromal Schizophrenia and Psychotic Disorders and remains completed. Sponsored by Janssen Pharmaceutica N.V., Belgium, it has been updated 5 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutica N.V., Belgium
Northwell Health
Pfizer
Stanley Medical Research Institute

Data source: Northwell Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Glen Oaks, United States